- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in via RCPCH
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- Podcasts
- About
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- Podcasts
- About
- Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in via RCPCH
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 109,Issue 3
- Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Review
Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences
- http://orcid.org/0000-0002-7477-7264Souvik Mitra1,2,3,
- Leah Whitehead2,
- Katie Smith4,
- Breagh Maclean5,
- Rebekah Nixon6,
- Andrew Veysey2,
- Marsha Campbell-Yeo1,2,7,
- Stefan Kuhle1,3,8,
- http://orcid.org/0000-0003-0707-876XChris Gale9,
- Roger Soll10,
- Jon Dorling1,3,6,
- Bradley C Johnston3,11,12
- 1Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
- 2Division of Neonatal Perinatal Medicine, IWK Health, Halifax, Nova Scotia, Canada
- 3Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
- 4School of Access, Education and Language, Nova Scotia Community College, Halifax, Nova Scotia, Canada
- 5Department of Service Nova Scotia, Government of Nova Scotia, Halifax, Nova Scotia, Canada
- 6Department of Neonatal Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 7School of Nursing, Faculty of Health, Dalhousie University, Halifax, Nova Scotia, Canada
- 8Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University of Mainz, Mainz, Germany
- 9School of Public Health, Imperial College London, London, UK
- 10Department of Pediatrics, University of Vermont, Burlington, New Jersey, USA
- 11Department of Nutrition, College of Agriculture and Life Sciences, Texas A&M University, College Station, Texas, USA
- 12Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, College Station, Texas, USA
- Correspondence to Dr Souvik Mitra, Division of Neonatal Perinatal Medicine, Department of Pediatrics, Dalhousie University & IWK Health, Halifax, Nova Scotia, Canada; souvik.mitra{at}iwk.nshealth.ca
Importance
Prophylactic cyclo-oxygenase inhibitors (COX-Is) such as indomethacin, ibuprofen and acetaminophen may prevent morbidity and mortality in extremely preterm infants (born ≤28 weeks’ gestation). However, there is controversy around which COX-I, if any, is the most effective and safest, which has resulted in considerable variability in clinical practice.
Our objective was to develop rigorous and transparent clinical practice guideline recommendations for the prophylactic use of COX-I drugs for the prevention of mortality and morbidity in extremely preterm infants.
The Grading of Recommendations Assessment, Development and Evaluation evidence-to-decision framework for multiple comparisons was used to develop the guideline recommendations. A 12-member panel, including 5 experienced neonatal care providers, 2 methods experts, 1 pharmacist, 2 parents of former extremely preterm infants and 2 adults born extremely preterm, was convened. A rating of the most important clinical outcomes was established a priori. Evidence from a Cochrane network meta-analysis and a cross-sectional mixed-methods study exploring family values and preferences were used as the primary sources of evidence.
The panel recommended that prophylaxis with intravenous indomethacin may be considered in extremely preterm infants (conditional recommendation, moderate certainty in estimate of effects). Shared decision making with parents was encouraged to evaluate their values and preferences prior to therapy. The panel recommended against routine use of ibuprofen prophylaxis in this gestational age group (conditional recommendation, low certainty in the estimate of effects). The panel strongly recommended against use of prophylactic acetaminophen (strong recommendation, very low certainty in estimate of effects) until further research evidence is available.
- Intensive Care Units, Neonatal
- Neonatology
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Intensive Care Units, Neonatal
- Neonatology
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
View Full Text
Footnotes
X @souvik_neo, @DrCGale
Contributors SM conceived the project under the mentorship of BCJ and JD. SM and BCJ cochaired the panel meetings. SM drafted the manuscript. SM, LW, KS, BM, RN, AV, MC-Y, SK, CG, RS, BCJ and JD reviewed all drafts and approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Linked Articles
- Highlights from this issue
Fantoms
Ben J Stenson
Archives of Disease in Childhood - Fetal and Neonatal Edition 2024; 109 229-229 Published Online First: 18 Apr 2024. doi: 10.1136/archdischild-2024-327233
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in via RCPCH
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in via RCPCH